Difference between revisions of "Vadimezan (AS-A404)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Warner-admin moved page Vadimezan (ASA-404) to Vadimezan (AS-A404) without leaving a redirect) |
Warner-admin (talk | contribs) m (Text replacement - "analogue" to "analog") |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vadimezan NCI Drug Dictionary]: A fused tricyclic | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vadimezan NCI Drug Dictionary]: A fused tricyclic analog of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages. |
==Also known as== | ==Also known as== | ||
Revision as of 13:50, 23 September 2023
Mechanism of action
From the NCI Drug Dictionary: A fused tricyclic analog of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
Also known as
- Code names: AS-1404, AS-A404